Four months after Avidity’s $12 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its predecessor ...

Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, ...

On March 10, 2026, from 12:00 p.m. -- 1:30 p.m. ET, in room Key West ABCD at the Hilton Orlando, Avidity will host an industry forum lunch titled "Biomarker Advancements in Rare Neuromuscular Disease: ...

Shares of Avidity Biosciences, Inc. (RNA) fell 20% in the pre-market session on Thursday after the company announced that it intends to offer and sell $500 million of shares of its common stock in an ...

We recently published 10 Stocks with Surprising Gains. Avidity Biosciences Inc. (NASDAQ:RNA) is one of the best performers on Friday. Avidity snapped a four-day losing streak on Friday, adding 9.02 ...

This is read by an automated voice. Please report any issues or inconsistencies here. San Diego-based Avidity Biosciences Inc. agreed to be acquired by Novartis AG in a deal valued at $12 billion.

It is being acquired for quite a meaty premium. The buyer is a top name in the global pharmaceuticals space. The purchasing party is global pharmaceutical company Novartis, which on Sunday divulged ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

Avidity Biosciences (RNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 7. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating ...

ALLISON GATLIN Wed, November 13, 2024 at 9:07 PM UTC 2 min read Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News ...

Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Avidity Biosciences (RNA – Research Report). The associated price target remains the same with $50.00. Yanan Zhu has given his Buy ...

While data on functional endpoints are still to come, Avidity Biosciences Inc. executives said the firm is moving ahead with plans for a BLA filing by the end of 2025 for del-zota, an ...